close

Inhibitex, Inc., a biopharmaceutical company, develops differentiated anti-infective products to prevent and treat serious infections primarily shingles and chronic hepatitis C. Its anti- infective product candidates include FV-100, an orally available nucleoside analogue prodrug, which completed Phase I trials used for the treatment of herpes zoster or shingles; and aurexis, a humanized monoclonal antibody, which completed Phase IIa trials used for the treatment of serious S. aureus infections. The company's preclinical product candidates include HCV polymerase inhibitors, which are used for the treatment of chronic HCV infection; HIV integrase inhibitors that are used for the treatment of HIV infection; and staphylococcal vaccines, an active vaccine to prevent S. aureus infections. It has MSCRAMM based license and collaboration agreement with Wyeth Pharmaceuticals for the development of staphylococcal vaccines; and royalty-bearing license agreement with Cardiff University and Katholieke Universiteit for intellectual property of HCV nucleoside polymerase inhibitors. Inhibitex, Inc. was founded in 1994 and is based in Alpharetta, Georgia.

(login to add this stock to your watchlist or favorites)

Key Statistics

Closing Price	26.00
Volume	0
Volume Avg	(mio) 3.92
52 Week High	26.01
52 Week Low	2.15
PE	N/A
PE (group average)	39
EPS Year	-0.36
EPS change Q/Q	-9.09%
EPS change Q/Q Yr ago	-50%
EPS change Q/Q next Q est	-33.33%
EPS change Y/Y	-10%
REV change Q/Q	0%
REV change Q/Q Yr ago	-70%
EPS next Q est	-0.09
EPS next Y est	-0.42
Divident Annual	0.00
Dividend Yield	0%